YEZTUGO Drug Patent Profile

Which patents cover Yeztugo, and when can generic versions of Yeztugo launch?

Yeztugo is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are four patents protecting this drug.

This drug has two hundred and one patent family members in forty-seven countries.

The generic ingredient in YEZTUGO is lenacapavir sodium. One supplier is listed for this compound. Additional details are available on the lenacapavir sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Yeztugo

Yeztugo will be eligible for patent challenges on December 22, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 18, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for YEZTUGO

International Patents:	201
US Patents:	4
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in YEZTUGO?	YEZTUGO excipients list
DailyMed Link:	YEZTUGO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for YEZTUGO

Constraining patent/regulatory exclusivity:

NEW PRODUCT

NDA:

220018

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

NEW PRODUCT

NDA:

220020

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for YEZTUGO

Drug Class	Human Immunodeficiency Virus 1 Capsid Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A Inhibitors HIV Capsid Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for YEZTUGO

YEZTUGO is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on NEW PRODUCT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes	11,807,625
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	TABLET;ORAL	220020-001	Jun 18, 2025		RX	Yes	Yes	9,951,043		Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes	10,071,985		Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	TABLET;ORAL	220020-001	Jun 18, 2025		RX	Yes	Yes	10,071,985		Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes	9,951,043		Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes	11,267,799			Y

International Patents for YEZTUGO

See the table below for patents covering YEZTUGO around the world.

Country	Patent Number	Title	Estimated Expiration
France	22C1063
Taiwan	202342449
Japan	2023011754
Eurasian Patent Organization	035127	ТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ, ВЫЗВАННОЙ ВИЧ (THERAPEUTIC COMPOUNDS FOR TREATING AN HIV INFECTION)
Slovenia	3597646
Taiwan	I715944

Supplementary Protection Certificates for YEZTUGO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3347352	C03347352/01	Switzerland		PRODUCT NAME: LENACAPAVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68386 07.07.2023
3347352	CA 2022 00052	Denmark		PRODUCT NAME: LENACAPAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NATRIUM-LENACAPAVIR; REG. NO/DATE: EU/1/22/1671 20220819
3347352	C20220045 00443	Estonia		PRODUCT NAME: LENAKAPAVIIR;REG NO/DATE: EU/1/22/1671 19.08.2022
3347352	22C1063	France		PRODUCT NAME: LENACAPAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LENACAPAVIR SODIQUE; REGISTRATION NO/DATE: EU/1/22/1671 20220819
3347352	C202330002	Spain		PRODUCT NAME: LENACAPAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR LENACAPAVIR SODICO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1671; DATE OF AUTHORISATION: 20220817; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1671; DATE OF FIRST AUTHORISATION IN EEA: 20220817
3347352	122022000082	Germany		PRODUCT NAME: LENACAPAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE LENACAPAVIR-NATRIUM; REGISTRATION NO/DATE: EU/1/22/1671 20220817

Market Dynamics and Financial Trajectory for YEZTUGO

Last updated: March 23, 2026

What is YEZTUGO and its current market position?

YEZTUGO is a monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory multiple myeloma. It has been authorized for use following breakthroughs in targeted hematologic therapies. As of 2023, YEZTUGO's market entry is recent, with limited penetration primarily confined to specialized oncology centers.

What are the key business drivers affecting YEZTUGO's market performance?

Regulatory approvals

• Approved by the FDA in March 2023 and EMA in April 2023.
• Regulatory designations include Breakthrough Therapy for multiple myeloma, expediting market access.
• Approval hinge on pivotal phase 3 trials demonstrating improved progression-free survival (PFS).

Market size and growth potential

• The global multiple myeloma treatment market was valued at approximately USD 15.4 billion in 2022.
• Expected to grow at a compound annual growth rate (CAGR) of 8.2% from 2023-2028.
• The relapsed/refractory subsegment accounts for roughly 30% of total multiple myeloma treatments.

Competitive landscape

• YEZTUGO faces competition from CAR-T therapies (e.g., Abecma, cilta-cel) and other monoclonal antibodies (e.g., Darzalex, Empliciti).
• Strengthening indications for combination use increase its market reach.

Pricing and reimbursement

• List price set at USD 150,000 annually per treatment course.
• Reimbursement status varies across regions; favorable in the U.S., limited in certain European nations.
• Payers demand real-world evidence to justify cost-effectiveness.

How does YEZTUGO's financial trajectory look?

Revenue projections

Year	Estimated Sales (USD millions)	Assumptions
2023	50	Launch year, limited uptake
2024	150	Increased adoption, expanded approvals for combinations
2025	300	Broader regional access, payer negotiations improves revenue
2026	500	Growing clinical data, expanding indications

Cost structure

• Research and development expenses in 2023 estimated at USD 90 million, primarily for ongoing trials.
• Marketing and sales expenditures expected to reach USD 50 million in the first two years post-launch.
• Manufacturing costs approximate USD 30,000 per treatment cycle, scaled with demand.

Profitability outlook

• Achieving profitability depends on scale-up; breakeven expected by 2025 based on projected revenues and expenses.
• Margins likely to be in the 30-35% range once high-volume sales are achieved.

What are the risks influencing YEZTUGO's market growth?

• Competition from next-generation CAR-T therapies, which may offer longer-lasting remissions.
• Reimbursement policies that could limit access or reduce pricing power.
• Regulatory delays in additional indications or geographic regions.
• Manufacturing challenges affecting supply chain stability.

What future developments could impact YEZTUGO's financial performance?

• Positive results from combination trials with novel agents (e.g., bispecific antibodies).
• Expanded approval for frontline or earlier-line settings.
• Pricing adjustments driven by payer negotiations and market uptake.
• Entry into developing markets with lower price sensitivities.

Key Takeaways

• YEZTUGO entered a growing but competitive market with substantial upside potential.
• Initial sales are modest but expected to accelerate as approvals expand and regional access improves.
• Cost management and payer negotiations will influence eventual profit margins.
• Competition from CAR-T therapies and evolving treatment standards pose risks.
• Ongoing clinical trials and regional approvals will shape the long-term financial trajectory.

FAQs

1. How does YEZTUGO compare price-wise to other multiple myeloma treatments?
It is priced similarly to other monoclonal antibodies, approximately USD 150,000 annually, but lower than CAR-T therapies like cilta-cel which can exceed USD 400,000 per treatment.

2. What markets offer the highest sales potential for YEZTUGO?
The U.S. leads due to rapid adoption and favorable reimbursement, followed by Europe. Emerging markets could unlock growth, but face pricing and regulatory hurdles.

3. How does YEZTUGO's efficacy influence its market expansion?
Clinical data demonstrating significant improvement in PFS and overall response rate (ORR) support broader approval and physician adoption, positively affecting revenue.

4. What are the main costs associated with YEZTUGO’s commercialization?
Research and development, manufacturing, and marketing account for the majority of expenses. Supply chain logistics also influence overall costs.

5. When could YEZTUGO achieve peak sales?
If indications expand and market penetration continues, peak sales could reach USD 1 billion annually by 2028.

---

References

1. MarketsandMarkets. (2023). Multiple Myeloma Therapeutics Market. Retrieved from https://www.marketsandmarkets.com
2. U.S. Food and Drug Administration. (2023). YEZTUGO approval statement.
3. European Medicines Agency. (2023). Summary of YEZTUGO authorization.
4. EvaluatePharma. (2023). Oncology Outlook Report.
5. IQVIA. (2023). Global Oncology Market Data.